Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 20, Issue 12, Pages 1662-1664Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458514523497
Keywords
Relapsing/remitting; disease-modifying therapies; fingolimod; amenorrhea
Categories
Ask authors/readers for more resources
Amenorrhea has not been reported as an adverse event in fingolimod phase III clinical trials in patients with multiple sclerosis (MS) with either 0.5 mg or 1.25 mg dosages. Here we report three cases of young women with MS who developed amenorrhea within 6 months of initiation of fingolimod. They experienced irregularities in their menstrual cycles in the first 3 months, which progressed to amenorrhea by 5th or 6th month. Gynecology evaluations showed no other etiologies. Menses returned to baseline after discontinuation of fingolimod for 2-3 months. Amenorrhea could be associated with fingolimod in the first year. Future surveillance is advised to determine the incidence rate of this adverse event.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available